Liu et al. detected CRT exposure and ATP and HMGB1 release in several human cancer cell lines (U2OS, HeLa, HCT-116) and mouse fibrosarcoma cells (MCA205) following treatment with various tyrosine kinase inhibitors, including: (R)-crizotinib, foretinib, canertinib, lestaurtinib, and ceritinib. This evidence concerns the gene HMGB1 and cancer.